The Burlington, Mass.-based company’s extended-release intra-articular injection combines a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix using Flexion’s microsphere technology.
The FDA approved Zilretta last month after granting it fast track status in 2015.
Flexion touts its therapy as the first of its kind, providing pain relief for up to 12 weeks without the use of opioids.
“We have assembled a remarkable team of Musculoskeletal Business Managers, and last week they concluded their training at the Zilretta national launch meeting,” president & CEO Dr. Michael Clayman said in prepared remarks.
“We have already begun the process of informing and educating physicians about the important role Zilretta can play in the management of OA knee pain. With its extended-release microsphere formulation, we believe Zilretta holds the potential to disrupt the current treatment paradigm, and we are thrilled that it is now broadly available for the millions of Americans confronting this relentless disease.”